Results 71 to 80 of about 1,680 (126)

Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis

São Paulo Medical Journal
BACKGROUND: Until recently, the treatment of people with hemophilia A and inhibitors (PwHAi) was based on the use of bypassing agents (BPA). However, the advent of emicizumab as prophylaxis has demonstrated promising results.
Tiago Paiva Prudente, Ricardo Mesquita Camelo, Rafael Alves Guimarães, Maria do Rosário Ferraz Roberti   +3 more
doaj   +1 more source

PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience

Bleeding, Thrombosis and Vascular Biology
Background and Aims: Hemophilia A (HA) is an hereditary X-linked bleeding disorder secondary to deficiency of the clotting factor VIII (FVIII), that, if not properly treated, is associated with debilitating joint damage due to recurrent hemarthroses as ...
doaj   +1 more source

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Drug Design, Development and Therapy, 2020
Sandra Le Quellec1,2 1Unité d’hémostase Clinique – Hôpital Cardiologique Louis Pradel – Hospices Civils de Lyon, Lyon, France; 2Service d’hématologie biologique, Groupement Hospitalier Est &ndash ...
Le Quellec S
doaj  

PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience

Bleeding, Thrombosis and Vascular Biology
Background and Aims: The role of prophylaxis in moderate hemophilia A (HA) patients is less clear than in severe HA, given their variable bleeding phenotype.
doaj   +1 more source

CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients

Bleeding, Thrombosis and Vascular Biology
Background: Prophylactic treatments to prevent bleeding are considered the standard therapy in Hemophilia A (HA) and inhibitor formation is the main complication of FVIII infusion.
doaj   +1 more source

Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A. [PDF]

Ther Adv Hematol
Dutta A, Dutta TS, Borboruah L, Duseja Y, Borah J, Gogoi P.   +5 more
europepmc   +1 more source

Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis. [PDF]

Blood Adv
Locke M, Albiez J, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T.   +8 more
europepmc   +1 more source

Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database. [PDF]

J Manag Care Spec Pharm
Lee JS, Schuldt R, Xia Z, Lee L, Biondo JML, Shapiro AD.   +5 more
europepmc   +1 more source

Paediatric Subanalysis of TSUBASA, Assessing Physical Activity, Bleeding, Quality of Life and Safety in People with Haemophilia A Receiving Emicizumab. [PDF]

TH Open
Nogami K, Amano K, Sawada A, Nagao A, Nagae C, Nojima M, Suzuki N, Kawano M, Shimura T, Sugao Y, Fujii T.   +10 more
europepmc   +1 more source

Evaluation of Autoimmune FVIII Inhibitor Using Clot Waveform Analysis in Emicizumab-Treated Patients. [PDF]

J Clin Med
Tamaki S, Wada H, Shinke N, Nishiki J, Sasao R, Fujieda A, Matsumoto T, Tawara I, Hashiguchi T.   +8 more
europepmc   +1 more source